CALMARE THERAPEUTICS (CTTC) Form 4 CALMARE THERAPEUTICS / Peter F Brennan ownership change

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:	3235-0287
Estimated average burden
hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Brennan Peter F

(Last) (First) (Middle)

1375 KINGS HIGHWAY EAST

(Street)

FAIRFIELD CT 06824

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CALMARE THERAPEUTICS Inc [ CTTC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/12/2018

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/12/2018		M		4,594,117	A	(1)(2)(3)(4)(5)	13,850,181	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Warrant	$0.6	02/12/2018		C		123,530		(1)	(1)	Common Stock	123,530	$0.6	123,530	D
Warrant	$0.6	02/12/2018		C		411,765		(2)	(2)	Common Stock	411,765	$0.6	535,295	D
Warrant	$0.13	02/12/2018		C		764,706		(3)	(3)	Common Stock	764,706	$0.13	1,300,001	D
Warrant	$0.13	02/12/2018		C		1,882,362		(4)	(4)	Common Stock	1,882,362	$0.13	3,182,353	D
Warrant	$0.125	02/12/2018		C		1,411,765		(5)	(5)	Common Stock	1,411,765	$0.125	4,594,117	D

Explanation of Responses:

1. The Reporting Person received a warrant to purchase 123,530 shares of Common Stock on 02/23/2017 inconnection with a Note Purchase Agreement executed on that date. The exercise price was $0.60 per share. The warrant was exercisable immediately and expired in one year-02/23/2018.

2. The Reporting Person received a warrant to purchase 411,765 shares of Common Stock on 05/16/2017 in connection with a Note Purchase Agreement executed on that date. The exercise price was $0.60 per share. The warrant was exercisable immediately and expired in one year-05/16/2018.

3. The Reporting Person received a warrant to purchase 764,706 shares of Common Stock on 07/24/2017 in connection with a Note Purchase Agreement executed on that date. The exercise price was $0.13 per share. The warrant was exercisable immediately and expired in one year - 07/24/2018.

4. The Reporting Person received a warrant to purchase 1,882,352 shares of Common Stock on 12/29/2017 in connection with a Note Purchase Agreement executed on that date. The exercise price was $0.13 per share. The warrant was exercisable immediately and expired in one year-12/29/2018.

5. The Reporting Person received a warrant to purchase 1,411,765 shares of Common Stock on 02/01/2018 in connection with a Note Purchase Agreement executed on that date. The exercise price was $0.125 per share. The warrant was exercisable immediately and expired in one year- 02/01/2019.

	/s/ Peter Brennan	03/06/2018
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.